- Home
- INZY vs FDMT Comparison
INZY vs FDMT Comparison
Compare INZY & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- FDMT
- Stock Information
- Founded
- INZY 2015
- FDMT 2013
- Country
- INZY United States
- FDMT United States
- Employees
- INZY N/A
- FDMT N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- INZY Health Care
- FDMT Health Care
- Exchange
- INZY Nasdaq
- FDMT Nasdaq
- Market Cap
- INZY 255.3M
- FDMT 207.1M
- IPO Year
- INZY 2020
- FDMT 2020
- Fundamental
- Price
- INZY $3.99
- FDMT $4.13
- Analyst Decision
- INZY Buy
- FDMT Buy
- Analyst Count
- INZY 9
- FDMT 10
- Target Price
- INZY $15.22
- FDMT $32.33
- AVG Volume (30 Days)
- INZY 1.3M
- FDMT 432.1K
- Earning Date
- INZY 08-05-2025
- FDMT 08-07-2025
- Dividend Yield
- INZY N/A
- FDMT N/A
- EPS Growth
- INZY N/A
- FDMT N/A
- EPS
- INZY N/A
- FDMT N/A
- Revenue
- INZY N/A
- FDMT $23,000.00
- Revenue This Year
- INZY N/A
- FDMT $14,927.03
- Revenue Next Year
- INZY N/A
- FDMT N/A
- P/E Ratio
- INZY N/A
- FDMT N/A
- Revenue Growth
- INZY N/A
- FDMT N/A
- 52 Week Low
- INZY $0.72
- FDMT $2.24
- 52 Week High
- INZY $6.24
- FDMT $28.93
- Technical
- Relative Strength Index (RSI)
- INZY 83.59
- FDMT 54.45
- Support Level
- INZY $3.94
- FDMT $4.21
- Resistance Level
- INZY $3.97
- FDMT $4.62
- Average True Range (ATR)
- INZY 0.01
- FDMT 0.30
- MACD
- INZY -0.10
- FDMT -0.02
- Stochastic Oscillator
- INZY 100.00
- FDMT 37.42
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.